GAITHERSBURG, Md. , March 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it is launching a collaboration with the University of Alabama at Birmingham (UAB) on the development of its single-dose, intranasal COVID-19

Conference Call & Webcast Scheduled for Friday, March 27, at 8:30 am Eastern Time GAITHERSBURG, Md. , March 27, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the year ended December 31, 2019 and provided a

GAITHERSBURG, Md. , March 25, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the year ended December 31, 2019 and host a conference call on Friday, March 27, 2020 .

GAITHERSBURG, Md. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the advancement of a novel single-dose, intranasal vaccine using Altimmune’s proprietary technology to protect against COVID-19, the disease caused by the

GAITHERSBURG, Md. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Vipin K. Garg , Ph.D., President and Chief Executive Officer will present at the Cowen 40 th Annual Health Care Conference in Boston on Monday, March

GAITHERSBURG, Md. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following conferences during the months of February:     2020 BIO CEO & Investor Conference Date:    Monday, February

Preclinical study shows systemic activity of ALT-702 following local administration Altimmune granted U.S. patent providing broad coverage of platform technology GAITHERSBURG, Md. , Jan. 23, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company today

GAITHERSBURG, Md. , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an oral presentation at the 2020 NASH-TAG Conference being held on January 9-11, 2020 in Park City, Utah.  Details for the oral presentation are as